Genmab A/S (GNMSF) News Today $201.18 -9.58 (-4.55%) (As of 11/19/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Barclays Reaffirms Their Buy Rating on Genmab A/S (0MGB)November 19 at 12:56 PM | markets.businessinsider.comShort Interest in Genmab A/S (OTCMKTS:GNMSF) Decreases By 10.1%Genmab A/S (OTCMKTS:GNMSF - Get Free Report) was the recipient of a significant drop in short interest in the month of October. As of October 31st, there was short interest totalling 76,300 shares, a drop of 10.1% from the October 15th total of 84,900 shares. Based on an average daily trading volume, of 16,400 shares, the short-interest ratio is currently 4.7 days.November 18 at 1:48 PM | marketbeat.comGenmab price target lowered to DKK 2,250 from DKK 2,500 at Deutsche BankNovember 14, 2024 | markets.businessinsider.comTruist Financial Sticks to Its Buy Rating for Genmab (GMAB)November 8, 2024 | markets.businessinsider.comGenmab’s Mixed Earnings and Strategic Developments Lead to Hold RatingNovember 8, 2024 | markets.businessinsider.comGenmab Reports Strong Growth and Strategic AdvancesNovember 7, 2024 | markets.businessinsider.comGenmab A/S (OTCMKTS:GNMSF) Stock Crosses Below 200 Day Moving Average - Here's What HappenedGenmab A/S (OTCMKTS:GNMSF) Stock Passes Below 200-Day Moving Average - Should You Sell?October 31, 2024 | marketbeat.comGenmab A/S (OTCMKTS:GNMSF) Shares Cross Below Two Hundred Day Moving Average - Time to Sell?Genmab A/S (OTCMKTS:GNMSF) Stock Price Crosses Below 200-Day Moving Average - Time to Sell?October 23, 2024 | marketbeat.comGenmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for Third Quarter of 2024October 17, 2024 | finanznachrichten.deGenmab A/S (GMAB): Leading Innovation in Antibody TherapeuticsOctober 17, 2024 | msn.comUBS Keeps Their Buy Rating on Genmab A/S (0MGB)October 16, 2024 | markets.businessinsider.comGenmab A/S (OTCMKTS:GNMSF) Hits New 52-Week Low - Time to Sell?Genmab A/S (OTCMKTS:GNMSF) Reaches New 52-Week Low - Here's What HappenedOctober 15, 2024 | marketbeat.comMorgan Stanley Reaffirms Their Hold Rating on Genmab (GMAB)October 15, 2024 | markets.businessinsider.comGenmab A/S (0MGB) Receives a Buy from BarclaysOctober 11, 2024 | markets.businessinsider.comGenmab A/S (GMAB): Among The Stocks With Biggest Upside Potential According to Hedge FundsOctober 9, 2024 | insidermonkey.comGenmab A/S (OTCMKTS:GNMSF) Short Interest UpdateGenmab A/S (OTCMKTS:GNMSF - Get Free Report) saw a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 206,200 shares, a growth of 11.1% from the August 15th total of 185,600 shares. Based on an average daily volume of 1,800 shares, the short-interest ratio is presently 114.6 days.September 18, 2024 | marketbeat.comInvestigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1 ...September 16, 2024 | businesswire.comGenmab A/S (OTCMKTS:GNMSF) Share Price Passes Below 200-Day Moving Average of $278.03Genmab A/S (OTCMKTS:GNMSF) Stock Price Crosses Below 200-Day Moving Average of $278.03September 12, 2024 | marketbeat.comUBS Sticks to Their Buy Rating for Genmab A/S (0MGB)September 11, 2024 | markets.businessinsider.comGenmab A/S (OTCMKTS:GNMSF) Stock Passes Above Fifty Day Moving Average of $264.64Genmab A/S (OTCMKTS:GNMSF) Stock Price Passes Above 50-Day Moving Average of $264.64September 4, 2024 | marketbeat.comStrong Pipeline and Regulatory Approval Prospects Affirm Buy Rating for GenmabAugust 27, 2024 | markets.businessinsider.comGenmab A/S (NASDAQ:GMAB) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | msn.comGenmab A/S (GMAB) Q2 2024 Earnings Call TranscriptAugust 12, 2024 | seekingalpha.comGenmab A/S (GMAB.CO)August 9, 2024 | au.finance.yahoo.comGenmab Takes Control of Lung Cancer Drug Development After BioNTech Exits ProgramAugust 5, 2024 | marketwatch.comStrong Buy on Genmab: Robust DARZALEX Sales and Promising Pipeline Drive Positive OutlookJuly 19, 2024 | markets.businessinsider.comGenmab A/S shares target raised on FDA approvalJune 27, 2024 | investing.comGenmab’s Buy Rating Affirmed by Promising Epcoritamab Trials and Regulatory MilestonesMay 20, 2024 | markets.businessinsider.comWhat 9 Analyst Ratings Have To Say About GenmabMay 20, 2024 | markets.businessinsider.comDanish biotech says companies should tap into China’s ‘impressive innovation’May 14, 2024 | finance.yahoo.comBuy Rating Affirmed for Genmab on Strong TIVDAK Approval and Promising Pipeline ValuationMay 1, 2024 | markets.businessinsider.comComstock Inc (LODE) Q1 2024 Earnings Call Transcript Highlights: Strategic Investments and ...May 1, 2024 | finance.yahoo.comGenmab Acquires A Missing Piece For Its PipelineApril 16, 2024 | seekingalpha.comGenmab's Q1 Darzalex Sales By Johnson & Johnson Reach $2.692 BlnApril 16, 2024 | markets.businessinsider.comTruist Financial Keeps Their Buy Rating on Genmab (GMAB)April 9, 2024 | markets.businessinsider.comProfoundBio discovers the joys of having a wealthy ownerApril 8, 2024 | benzinga.com30 Biggest Biotechnology Companies in the WorldMarch 17, 2024 | finance.yahoo.comPassing of Genmab A/S’ Annual General MeetingMarch 13, 2024 | finance.yahoo.comGenmab: Recent Updates Support The Growth NarrativeFebruary 21, 2024 | seekingalpha.com4 Analysts Assess Genmab: What You Need To KnowFebruary 20, 2024 | markets.businessinsider.comGenmab A/S’ New Regulation Risk – A Cause for Worry?February 15, 2024 | msn.comGenmab A/S (NASDAQ:GMAB) Q4 2023 Earnings Call TranscriptFebruary 15, 2024 | finance.yahoo.comNotice to Convene the Annual General Meeting of Genmab A/SFebruary 15, 2024 | finance.yahoo.comGenmab Files Annual Report with the U.S. Securities and Exchange CommissionFebruary 14, 2024 | finance.yahoo.comGenmab: Growth Is Still a Better ChoiceFebruary 14, 2024 | finance.yahoo.comTisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical CancerFebruary 2, 2024 | finance.yahoo.comCracking The Code: Understanding Analyst Reviews For GenmabJanuary 29, 2024 | markets.businessinsider.comGrant of Restricted Stock Units and Warrants to Employees in GenmabJanuary 25, 2024 | finance.yahoo.comGenmab Announces Decision in Arbitration Appeal under License Agreement with JanssenJanuary 22, 2024 | finance.yahoo.comHRMY or GMAB: Which Is the Better Value Stock Right Now?December 7, 2023 | finance.yahoo.com Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GNMSF and its competitors with MarketBeat's FREE daily newsletter. Email Address “This Changes Everything” - Trump Hands Millions Massive IRS Gift (Ad)Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in… >> YES! Send Me My FREE Gold Guide! GNMSF Media Mentions By Week GNMSF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GNMSF News Sentiment▼0.660.36▲Average Medical News Sentiment GNMSF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GNMSF Articles This Week▼31▲GNMSF Articles Average Week Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GNMSF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 4Front Ventures News Today Algernon Pharmaceuticals News Today Allstar Health Brands News Today American Premium Mining News Today Anew Medical News Today Arno Therapeutics News Today AstraZeneca News Today AVVAA World Health Care Products News Today Basilea Pharmaceutica News Today BriaCell Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:GNMSF) was last updated on 11/20/2024 by MarketBeat.com Staff From Our PartnersAmazon's $150B Data Center Bet—What It Means for Uranium InvestorsAmazon is placing a massive bet on nuclear energy to power its $150 billion data center expansion. With dem...The Bull Report | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purpose...Priority Gold | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNMSF Stock Alerts